Abstract:Cerebral small vessel disease (SVD) causes lacunar stroke and intracerebral hemorrhage, and is the most common pathology underlying vascular cognitive impairment. Increasingly, the importance of other clinical features of SVD is being recognized including motor impairment, (vascular) parkinsonism, impaired balance, falls, and behavioral symptoms, such as depression, apathy, and personality change. Epidemiological data show a high prevalence of the characteristic magnetic resonance imaging (MRI) features of white matter hyperintensities and lacunar infarcts in community studies, and recent data suggest that it is also a major health burden in low- and middle-income countries. In this review, we cover advances in diagnosis, imaging, clinical presentations, pathogenesis, and treatment.The two most common pathologies underlying SVD are arteriolosclerosis caused by aging, hypertension, and other conventional vascular risk factors, and cerebral amyloid angiopathy (CAA) caused by vascular deposition of β-amyloid. We discuss the revised Boston criteria of CAA based on MRI features, which have been recently validated. Imaging is providing important insights into pathogenesis, including improved detection of tissue damage using diffusion tensor imaging (DTI) leading to its use to monitor progression and surrogate endpoints in clinical trials. Advanced MRI techniques can demonstrate functional or dynamic abnormalities of the blood vessels, while the high spatial resolution provided by ultrahigh field MRI at 7 T allows imaging of individual perforating arteries for the first time, and the measurement of flow velocity and pulsatility within these arteries. DTI and structural network analysis have highlighted the importance of network disruption in mediating the effect of different SVD pathologies in causing a number of symptoms, including cognitive impairment, apathy, and gait disturbance.Despite the public health importance of SVD, there are few proven treatments. We review the evidence for primary prevention, and recent data showing how intensive blood pressure lowering reduces white matter hyperintensities (WMH) progression and delays the onset of cognitive impairment. There are few treatments for secondary prevention, but a number of trials are currently evaluating novel treatment approaches. Recent advances have implicated molecular processes related to endothelial dysfunction, nitric oxide synthesis, blood-brain barrier integrity, maintenance and repair of the extracellular matrix, and inflammation. Novel treatment approaches are being developed to a number of these targets. Finally, we highlight the importance of large International collaborative initiatives in SVD to address important research questions and cover a number which have recently been established.

Extracellular matrix inflammation in vascular cognitive impairment and dementia

Neuroinflammation in Vascular Cognitive Impairment and Dementia: Current Evidence, Advances, and Prospects

Chronic cerebral hypoperfusion alters the CypA-EMMPRIN-gelatinase pathway: Implications for vascular dementia

Pathologic sequelae of vascular cognitive impairment and dementia sheds light on potential targets for intervention

Vascular cognitive impairment: Modeling a critical neurologic disease in vitro and in vivo

Vascular Tight Junction Disruption and Angiogenesis in Spontaneously Hypertensive Rat with Neuroinflammatory White Matter Injury.

Inflammation, apoptosis and autophagy as critical players in vascular dementia

Endothelial damage, vascular bagging and remodeling of the microvascular bed in human microangiopathy with deep white matter lesions

Brain endothelial cell activation and dysfunction associate with and contribute to the development of enlarged perivascular spaces and cerebral small vessel disease

Targeting VCAM1 to reduce neuroinflammation in ischemia‐triggered vascular dementia

Time-course of glial changes in the hyperhomocysteinemia model of vascular cognitive impairment and dementia (VCID)

Cerebral small vessel disease alters neurovascular unit regulation of microcirculation integrity involved in vascular cognitive impairment

Cerebral small vessel disease: Recent advances and future directions

Consensus statement for diagnosis of subcortical small vessel disease

Deep Microbleeds and Periventricular White Matter Disintegrity Are Independent Predictors of Attention/executive Dysfunction in Non-Dementia Patients with Small Vessel Disease.

Emerging Role of Immunity in Cerebral Small Vessel Disease

Regional contribution of vascular dysfunction in white matter dementia: clinical and neuropathological insights

Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment

Pathogenesis of white matter changes in cerebral small vessel diseases: beyond vessel-intrinsic mechanisms

Abstract WMP52: Markers Of Endothelial Glycocalyx Damage In Patients Withvascular Cognitive Impairment Associated With Cerebral Small Vessel Disease

Vascular Cognitive Impairment—The Molecular Basis and Potential Influence of the Gut Microbiota on the Pathological Process